An individual partnering theme concerning a malignant tumor project that, following evaluation by multiple pharmaceutical companies, culminated in an exclusive license agreement with Mitsubishi Tanabe Pharma, the achievement of a development milestone related to the start of clinical trials, and the receipt of milestone revenue.